on Biophytis (EPA:ALBPS)
Biophytis Announces Combined General Meeting for April 2024
Biophytis SA, a clinical-stage biotechnology company focusing on age-related disease therapeutics, declared it will conduct its Combined General Meeting (CGM) on April 2, 2024. The meeting is scheduled to take place at Sorbonne Université in Paris, with details published in the Bulletin des Annonces Légales Obligatoires.
The company encourages shareholders to vote in advance using several methods available, including postal votes, proxy votes through the Chairman, or the VOTACCESS platform, with deadlines set for March 30 and April 1, 2024, respectively.
Biophytis is known for its work on developing treatments targeting the degenerative processes of aging and improving patients' lives with age-related conditions. The company's notable drug candidate, RuvembriTM, is under development for several age-related diseases, showing promising results in clinical studies.
R. H.Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Biophytis news